Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Data: CivicScience; Chart: Axios Visuals

The U.S. will probably run out of adults who are enthusiastic about getting vaccinated within the next two to four weeks, according to a KFF analysis published yesterday.

Between the lines: Vaccine hesitancy is rapidly approaching as our main impediment to herd immunity.

  • "It appears we are quite close to the tipping point where demand for rather than supply of vaccines is our primary challenge," the authors write.
  • "Federal, state, and local officials, and the private sector, will face the challenge of having to figure out how to increase willingness to get vaccinated among those still on the fence, and ideally among the one-fifth of adults who have consistently said they would not get vaccinated or would do so only if required."

Related: Republicans who say they don't want to get the vaccine are becoming only more resistant, the Washington Post reports.

  • "The further we go into the vaccination process, the more passionate the hesitancy is," Frank Luntz, a longtime GOP communications expert, said after a Zoom focus group session last weekend. "If you've refused to take the vaccine this long, it's going to be hard to switch you."
  • Participants in the focus group said they were concerned by the prospect of booster shots, and most said they would want a fake vaccination card.

Go deeper

Apr 20, 2021 - Health

Swedish health agency: Those under 65 should receive different vaccine than AstraZeneca's for second dose

A Swedish woman receiving the Pfizer-BioNTech vaccine. Photo: Fredrik Sandberg/TT News Agency/AFP via Getty Images

The Swedish Health Agency on Tuesday recommended that people under 65 years old who received the first shot of the AstraZeneca coronavirus vaccine should get a different vaccine for the second shot.

Why it matters: There are no definitive studies regarding immune responses when initial and follow-up vaccine doses are different. The agency said that when results on mixing different doses are released they will evaluate whether the recommendation should be changed.

Apr 20, 2021 - Health

Johnson & Johnson to resume COVID vaccine rollout in Europe

Photo: Tom Williams/CQ-Roll Call, Inc via Getty Images

Johnson & Johnson announced Tuesday it would resume the rollout of its coronavirus vaccine in Europe after the European Medicines Agency (EMA) said unusual blood clots should be listed as a "very rare" side effect of the company's vaccine, but that the benefits of the shot still outweigh the risks.

Why it matters: Johnson & Johnson was set to send 50 million doses of its one-shot coronavirus vaccine to the European Union before it delayed it's European rollout earlier in April "out of an abundance of caution" over rare blood clotting events.

Apr 20, 2021 - Health

EU regulator: Benefits of J&J vaccine outweigh risk of rare blood clots

Photo: Allen J. Schaben / Los Angeles Times via Getty Images

The European Medicines Agency (EMA) said Tuesday that unusual blood clots should be listed as a "very rare" side effect of Johnson & Johnson's coronavirus vaccine, but that the benefits of the shot still outweigh the risks.

Why it matters: The agency's determination of a "possible link" to a rare kind of blood clot comes ahead of an expected ruling by the U.S. FDA this week on whether to lift its pause on the J&J vaccine rollout.